Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells

Item Type:	Article
Title:	Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells
Creators Name:	Yusenko, M.V. and Trentmann, A. and Andersson, M.K. and Ghani, L.A. and Jakobs, A. and Arteaga Paz, M.F. and Mikesch, J.H. and von Kries, J.P. and Stenman, G. and Klempnauer, K.H.
Abstract:	The master transcriptional regulator MYB is a key oncogenic driver in several human neoplasms, particularly in acute myeloid leukemia (AML) and adenoid cystic carcinoma (ACC). MYB is therefore an attractive target for drug development in MYB-activated malignancies. Here, we employed a MYB-reporter cell line and identified the polyether ionophores monensin, salinomycin, and nigericin as novel inhibitors of MYB activity. As a proof of principle, we show that monensin affects the expression of a significant number of MYB-regulated genes in AML cells and causes down-regulation of MYB expression, loss of cell viability, and induction of differentiation and apoptosis. Furthermore, monensin significantly inhibits proliferation of primary murine AML cells but not of normal hematopoietic progenitors, reflecting a high MYB-dependence of leukemic cells and underscoring the efficacy of monensin in MYB-activated malignancies. Importantly, monensin also suppressed the viability and non-adherent growth of adenoid cystic carcinoma (ACC) cells expressing MYB-NFIB fusion oncoproteins. Our data show that a single compound with significant MYB-inhibitory activity is effective against malignant cells from two distinct MYB-driven human neoplasms. Hence, monensin and related compounds are promising molecular scaffolds for development of novel MYB inhibitors.
Keywords:	MYB, AML, ACC, Monensin, Salinomycin, Polyether Ionophore, Animals, Mice
Source:	Cancer Letters
ISSN:	0304-3835
Publisher:	Elsevier
Volume:	479
Page Range:	61-70
Date:	1 June 2020
Official Publication:	https://doi.org/10.1016/j.canlet.2020.01.039
PubMed:	View item in PubMed

Repository Staff Only: item control page